AMA0076, a novel, locally acting rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 2, 2014, Pages 1006-1016

  Van de Velde, Sarah ^a   Van Bergen, Tine ^a   Sijnave, Davine ^a   Hollanders, Karolien ^a   Castermans, Karolien ^b   Defert, Olivier ^b   Leysen, Dirk ^b   Vandewalle, Evelien ^a,c   Moons, Lieve ^a   Stalmans, Ingeborg ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Amakem Ophthalmics   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Glaucoma; IOP lowering; ROCK inhibitors

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL) CYCLOHEXANECARBOXAMIDE; AMA0076; BIMATOPROST; LATANOPROST; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; VISCOELASTIC SUBSTANCE; Y 39983;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; HUMAN; HUMAN CELL; HYPEREMIA; HYPERTENSION; INTRAOCULAR PRESSURE; KINETICS; MALE; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; RABBIT; SINGLE DRUG DOSE; TRABECULAR MESHWORK;

GLAUCOMA; IOP LOWERING; ROCK INHIBITORS;

ACTINS; AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZOATES; CONJUNCTIVA; DISEASE MODELS, ANIMAL; FOCAL ADHESIONS; HYPEREMIA; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; PROTEIN KINASE INHIBITORS; PYRIDINES; RABBITS; RHO-ASSOCIATED KINASES; TONOMETRY, OCULAR; TRABECULAR MESHWORK; VINCULIN;

EID: 84894099557     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13157     Document Type: Article

References (51)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82:844-851.
2. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary openangle glaucoma. N Engl J Med. 2009;360:1113-1124.
3. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711-1720.
4. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487-497.
5. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
6. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720; discussion 829-730.
7. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
8. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713; discussion 829-730.
9. Peeters A, Webers CA, Prins MH, Zeegers MP, Hendrikse F, Schouten JS. Quantifying the effect of intraocular pressure reduction on the occurrence of glaucoma. Acta Ophthalmol. 2010;88:5-11.
10. Toris CB, Yablonski ME, Wang YL, Camras CB. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol. 1999; 127:407-412.
11. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005;24:612-637.
12. Johnson M. 'What controls aqueous humour outflow resistance?' Exp Eye Res. 2006;82:545-557.
13. Stamer WD, Acott TS. Current understanding of conventional outflow dysfunction in glaucoma. Curr Opin Ophthalmol. 2012;23:135-143.
14. Ferrer E. Trabecular meshwork as a new target for the treatment of glaucoma. Drug News Perspect. 2006;19:151-158.
15. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005;62:691-699.
16. Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin Pharmacother. 2007;8:3237-3249.
17. Munoz-Negrete FJ, Perez-Lopez M, Won Kim HR, Rebolleda G. New developments in glaucoma medical treatment [in Spanish]. Arch Soc Esp Oftalmol. 2009;84:491-500.
18. Llobet A, Gasull X, Gual A. Understanding trabecular meshwork physiology: a key to the control of intraocular pressure? News Physiol Sci. 2003;18:205-209.
19. Stumpff F, Wiederholt M. Regulation of trabecular meshwork contractility. Ophthalmologica. 2000;214:33-53.
20. Wiederholt M. Direct involvement of trabecular meshwork in the regulation of aqueous humor outflow. Curr Opin Ophthalmol. 1998;9:46-49.
21. Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol. 2003;48(suppl 1);S17-S20.
22. Honjo M, Inatani M, Kido N, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol. 2001;119:1171-1178.
23. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137-144.
24. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029-1037.
25. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216-3222.
26. Colligris B, Crooke A, Huete F, Pintor J. Potential role of Rhoassociated protein kinase inhibitors for glaucoma treatment. Recent Pat Endocr Metab Immune Drug Discov. 2012;6:89-98.
27. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007; 21:167-177.
28. Mandell KJ, Kudelka RM, Wirostko B. Rho kinase inhibitors for treatment of glaucoma. Exp Rev Ophthalmol. 2011;6:611-622.
29. Bodor N, Buchwald P. Retrometabolic drug design: principles and recent developments. Pure Appl Chem. 2008;80:1669-1682.
30. Boland S, Defert O, Alen J, et al. 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors. Bioorg Med Chem Lett. 2013;23:6442-6446.
31. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol. 2011; 29:1039-1045.
32. Ogundele AB, Earnest D, McLaughlin MA. In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%. Clin Ophthalmol. 2010;4: 649-652.
33. Ramachandran C, Patil RV, Combrink K, Sharif NA, Srinivas SP. Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells. Mol Vis. 2011;17:1877-1890.
34. Sjoquist B, Basu S, Byding P, Bergh K, Stjernschantz J. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Dispos. 1998;26:745-754.
35. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev. 2000;20:58-101.
36. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126:309-315.
37. Dinslage S, McLaren J, Brubaker R. Intraocular pressure in rabbits by telemetry II: effects of animal handling and drugs. Invest Ophthalmol Vis Sci. 1998;39:2485-2489.
38. Ishii K, Tomidokoro A, Nagahara M, et al. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Invest Ophthalmol Vis Sci. 2001;42: 2957-2963.
39. Orihashi M, Shima Y, Tsuneki H, Kimura I. Potent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbits. Biol Pharm Bull. 2005;28:65-68.
40. Gupta SK, Agarwal R, Galpalli ND, Srivastava S, Agrawal SS, Saxena R. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma. Methods Find Exp Clin Pharmacol. 2007;29:665-671.
41. Pintor J, Pelaez T, Peral A. Adenosine tetraphosphate, Ap4, a physiological regulator of intraocular pressure in normotensive rabbit eyes. J Pharmacol Exp Ther. 2004;308:468-473.
42. Sarchahi AAG, Toghraie, FS. Effects of latanoprost and pilocarpine combination on the intraocular pressure and pupil size of normal rabbits. Iran J Vet Res. 2011;12:298-303.
43. Gregory DS. Timolol reduces IOP in normal NZW rabbits during the dark only. Invest Ophthalmol Vis Sci. 1990;31:715-721.
44. Lee TC, Kiuchi Y, Gregory DS. Light exposure decreases IOP in rabbits during the night. Curr Eye Res. 1995;14:443-448.
45. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142.
46. Higashide T, Sugiyama K. Use of viscoelastic substance in ophthalmic surgery-focus on sodium hyaluronate. Clin Ophthalmol. 2008;2:21-30.
47. Benozzi J, Nahum LP, Campanelli JL, Rosenstein RE. Effect of hyaluronic acid on intraocular pressure in rats. Invest Ophthalmol Vis Sci. 2002;43:2196-2200.
48. Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 1997; 41(suppl 2):S69-S75.
49. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002;47(suppl 1):S53-S64.
50. Fautsch MP, Johnson DH. Aqueous humor outflow: what do we know? Where will it lead us? Invest Ophthalmol Vis Sci. 2006;47:4181-4187.
51. Zhang M, Maddala R, Rao PV. Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork. Am J Physiol Cell Physiol. 2008;295:C1057-C1070.